Compare ERII & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERII | PROK |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.7M | 359.4M |
| IPO Year | 2008 | 2021 |
| Metric | ERII | PROK |
|---|---|---|
| Price | $7.22 | $1.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $7.50 | ★ $7.88 |
| AVG Volume (30 Days) | 873.2K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,987,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $44.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $6.25 | $0.87 |
| 52 Week High | $16.30 | $2.65 |
| Indicator | ERII | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 33.21 |
| Support Level | $6.40 | $0.87 |
| Resistance Level | $9.18 | $2.01 |
| Average True Range (ATR) | 0.30 | 0.15 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 67.35 | 23.43 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.